id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-293389-3h9vsc1a	Risitano, Antonio M.	Complement as a target in COVID-19?	2020-04-23		.txt	text/plain	1069	53	34	Most patients who become critically ill following infection with SARS-CoV-2, the causative agent of COVID-19, develop acute respiratory distress syndrome (ARDS) 1 . The prominent decrease in lung-infiltrating neutrophils and the reduced levels of both intrapulmonary and plasma IL-6 seen in SARS-CoV-infected C3-deficient mice suggests the potential of combining C3 inhibitors with anti-IL-6 regimens. A recent preprint study reported that lung biopsy samples from patients with severe COVID-19 showed widespread complement activation, characterized by C3a generation and C3-fragment deposition 6 . Proximal complement inhibitors (which target C3 or its upstream activators) could be more effective, but these are still in clinical development, and none has yet been approved, although limited data from phase II clinical trials are available. However, the combination of clinical indicators of ARDS progression with known biomarkers of inflammation (C-reactive protein, plasma IL-6 levels and ferritin) would allow identification of patients that could benefit from complement inhibition.	./cache/cord-293389-3h9vsc1a.txt	./txt/cord-293389-3h9vsc1a.txt